Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Cell

Volumn 172, Issue 3, 2018, Pages 578-589.e17

  Janes, Matthew R ^a   Zhang, Jingchuan ^a   Li, Lian Sheng ^a   Hansen, Rasmus ^a   Peters, Ulf ^a   Guo, Xin ^a   Chen, Yuching ^a   Babbar, Anjali ^a   Firdaus, Sarah J ^a   Darjania, Levan ^a   Feng, Jun ^a   Chen, Jeffrey H ^a   Li, Shuangwei ^a   Li, Shisheng ^a   Long, Yun O ^a   Thach, Carol ^a   Liu, Yuan ^a   Zarieh, Ata ^a   Ely, Tess ^a   Kucharski, Jeff M ^a   Kessler, Linda V ^a   Wu, Tao ^a   Yu, Ke ^a   Wang, Yi ^a   Yao, Yvonne ^a   Deng, Xiaohu ^a   Zarrinkar, Patrick P ^a   Brehmer, Dirk ^b   Dhanak, Dashyant ^b   Lorenzi, Matthew V ^b   Hu Lowe, Dana ^a   Patricelli, Matthew P ^a   Ren, Pingda ^a,c   Liu, Yi ^a,c   more..

^a Wellspring Biosciences   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Kura Oncology   (United States)

Author keywords

3D culture; addiction; ARS 1620; dependence; G12C; KRAS; NSCLC; oncogene; RAS

Indexed keywords

ARS 1620; HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN P21;

A-549 CELL LINE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL LINE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; GENE MUTATION; HCT 116 CELL LINE; IN VIVO STUDY; LU65 CELL LINE; MIA PACA-2 CELL LINE; MOLECULARLY TARGETED THERAPY; MONOLAYER CULTURE; NCI-H358 CELL LINE; NCI-H441 CELL LINE; ONCOGENE K RAS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUMOR MODEL; TUMOR REGRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; MOLECULAR DOCKING; MOUSE; MUTATION; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HCT116 CELLS; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR DOCKING SIMULATION; MUTATION; NEOPLASMS, EXPERIMENTAL; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85041926583     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.01.006     Document Type: Article

References (56)

1. Athuluri-Divakar, S.K., Vasquez-Del Carpio, R., Dutta, K., Baker, S.J., Cosenza, S.C., Basu, I., Gupta, Y.K., Reddy, M.V., Ueno, L., Hart, J.R., et al. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling. Cell 165 (2016), 643–655.
2. Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.M., Gingras, M.C., Miller, D.K., Christ, A.N., Bruxner, T.J., Quinn, M.C., et al., Australian Pancreatic Cancer Genome Initiative. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531 (2016), 47–52.
3. Barbie, D.A., Tamayo, P., Boehm, J.S., Kim, S.Y., Moody, S.E., Dunn, I.F., Schinzel, A.C., Sandy, P., Meylan, E., Scholl, C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 (2009), 108–112.
4. Bild, A.H., Yao, G., Chang, J.T., Wang, Q., Potti, A., Chasse, D., Joshi, M.B., Harpole, D., Lancaster, J.M., Berchuck, A., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006), 353–357.
5. Bos, J.L., ras oncogenes in human cancer: a review. Cancer Res. 49 (1989), 4682–4689.
6. Burns, M.C., Sun, Q., Daniels, R.N., Camper, D., Kennedy, J.P., Phan, J., Olejniczak, E.T., Lee, T., Waterson, A.G., Rossanese, O.W., Fesik, S.W., Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc. Natl. Acad. Sci. USA 111 (2014), 3401–3406.
7. Campbell, J.D., Alexandrov, A., Kim, J., Wala, J., Berger, A.H., Pedamallu, C.S., Shukla, S.A., Guo, G., Brooks, A.N., Murray, B.A., et al., Cancer Genome Atlas Research Network. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 48 (2016), 607–616.
8. Chen, V.B., Arendall, W.B. 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., Murray, L.W., Richardson, J.S., Richardson, D.C., MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 12–21.
9. Chiaradonna, F., Sacco, E., Manzoni, R., Giorgio, M., Vanoni, M., Alberghina, L., Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 25 (2006), 5391–5404.
10. Cox, A.D., Fesik, S.W., Kimmelman, A.C., Luo, J., Der, C.J., Drugging the undruggable RAS: Mission possible?. Nat. Rev. Drug Discov. 13 (2014), 828–851.
11. Downward, J., Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003), 11–22.
12. Dry, J.R., Pavey, S., Pratilas, C.A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70 (2010), 2264–2273.
13. Ekert, J.E., Johnson, K., Strake, B., Pardinas, J., Jarantow, S., Perkinson, R., Colter, D.C., Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro–implication for drug development. PLoS ONE, 9, 2014, e92248.
14. Evelyn, C.R., Duan, X., Biesiada, J., Seibel, W.L., Meller, J., Zheng, Y., Rational design of small molecule inhibitors targeting the Ras GEF, SOS1. Chem. Biol. 21 (2014), 1618–1628.
15. Fujita-Sato, S., Galeas, J., Truitt, M., Pitt, C., Urisman, A., Bandyopadhyay, S., Ruggero, D., McCormick, F., Enhanced MET translation and signaling sustains K-Ras-driven proliferation under anchorage-independent growth conditions. Cancer Res. 75 (2015), 2851–2862.
16. Giannakis, M., Mu, X.J., Shukla, S.A., Qian, Z.R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 15 (2016), 857–865.
17. Hayes, T.K., Neel, N.F., Hu, C., Gautam, P., Chenard, M., Long, B., Aziz, M., Kassner, M., Bryant, K.L., Pierobon, M., et al. Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression. Cancer Cell 29 (2016), 75–89.
18. Howes, A.L., Richardson, R.D., Finlay, D., Vuori, K., 3-Dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems. PLoS ONE, 9, 2014, e108283.
19. Johnson, K.A., Fitting enzyme kinetic data with KinTek Global Kinetic Explorer. Methods Enzymol. 467 (2009), 601–626.
20. Jordan, E.J., Kim, H.R., Arcila, M.E., Barron, D., Chakravarty, D., Gao, J., Chang, M.T., Ni, A., Kundra, R., Jonsson, P., et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 7 (2017), 596–609.
21. Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.J., Sadanandam, A., Hu, B., et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158 (2014), 185–197.
22. Kwong, L.N., Boland, G.M., Frederick, D.T., Helms, T.L., Akid, A.T., Miller, J.P., Jiang, S., Cooper, Z.A., Song, X., Seth, S., et al. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J. Clin. Invest. 125 (2015), 1459–1470.
23. Lamba, S., Russo, M., Sun, C., Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Di Nicolantonio, F., Bardelli, A., RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep. 8 (2014), 1475–1483.
24. Lanning, B.R., Whitby, L.R., Dix, M.M., Douhan, J., Gilbert, A.M., Hett, E.C., Johnson, T.O., Joslyn, C., Kath, J.C., Niessen, S., et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat. Chem. Biol. 10 (2014), 760–767.
25. Leshchiner, E.S., Parkhitko, A., Bird, G.H., Luccarelli, J., Bellairs, J.A., Escudero, S., Opoku-Nsiah, K., Godes, M., Perrimon, N., Walensky, L.D., Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc. Natl. Acad. Sci. USA 112 (2015), 1761–1766.
26. Li, L., Feng, J., Wu, T., Ren, P., Liu, Y., and Long, Y.O. (2015). Inhibitors of KRAS G12C. Patent WO2015054572 A1, filed October 10, 2014, and published April 16, 2015.
27. Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J.P., Tamayo, P., The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1 (2015), 417–425.
28. Lim, S.M., Westover, K.D., Ficarro, S.B., Harrison, R.A., Choi, H.G., Pacold, M.E., Carrasco, M., Hunter, J., Kim, N.D., Xie, T., et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew. Chem. Int. Ed. Engl. 53 (2014), 199–204.
29. Lito, P., Solomon, M., Li, L.S., Hansen, R., Rosen, N., Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351 (2016), 604–608.
30. Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S.J., Jones, L.H., Gray, N.S., Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20 (2013), 146–159.
31. MacLean, B., Tomazela, D.M., Shulman, N., Chambers, M., Finney, G.L., Frewen, B., Kern, R., Tabb, D.L., Liebler, D.C., MacCoss, M.J., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26 (2010), 966–968.
32. Margarit, S.M., Sondermann, H., Hall, B.E., Nagar, B., Hoelz, A., Pirruccello, M., Bar-Sagi, D., Kuriyan, J., Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell 112 (2003), 685–695.
33. Maurer, T., Garrenton, L.S., Oh, A., Pitts, K., Anderson, D.J., Skelton, N.J., Fauber, B.P., Pan, B., Malek, S., Stokoe, D., et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. USA 109 (2012), 5299–5304.
34. McDonald, E.R. 3rd, de Weck, A., Schlabach, M.R., Billy, E., Mavrakis, K.J., Hoffman, G.R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell 170 (2017), 577–592.
35. Ostrem, J.M., Shokat, K.M., Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat. Rev. Drug Discov. 15 (2016), 771–785.
36. Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A., Shokat, K.M., K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503 (2013), 548–551.
37. Patgiri, A., Yadav, K.K., Arora, P.S., Bar-Sagi, D., An orthosteric inhibitor of the Ras-Sos interaction. Nat. Chem. Biol. 7 (2011), 585–587.
38. Patricelli, M.P., Janes, M.R., Li, L.S., Hansen, R., Peters, U., Kessler, L.V., Chen, Y., Kucharski, J.M., Feng, J., Ely, T., et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6 (2016), 316–329.
39. Pickl, M., Ries, C.H., Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28 (2009), 461–468.
40. Pylayeva-Gupta, Y., Grabocka, E., Bar-Sagi, D., RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11 (2011), 761–774.
41. Selby, M., Delosh, R., Laudeman, J., Ogle, C., Reinhart, R., Silvers, T., Lawrence, S., Kinders, R., Parchment, R., Teicher, B.A., Evans, D.M., 3D models of the NCI60 cell lines for screening oncology compounds. SLAS Discov. 22 (2017), 473–483.
42. Shao, D.D., Xue, W., Krall, E.B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A.C., Sood, S., Rosenbluh, J., Kim, J.W., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158 (2014), 171–184.
43. Shima, F., Yoshikawa, Y., Matsumoto, S., Kataoka, T., Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras.GTP-effector interaction. Enzymes 34 Pt. B (2013), 1–23.
44. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., Settleman, J., A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15 (2009), 489–500.
45. Stepan, A.F., Walker, D.P., Bauman, J., Price, D.A., Baillie, T.A., Kalgutkar, A.S., Aleo, M.D., Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 24 (2011), 1345–1410.
46. Strelow, J.M., A perspective on the kinetics of covalent and irreversible inhibition. SLAS Discov. 22 (2017), 3–20.
47. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
48. Sun, Q., Burke, J.P., Phan, J., Burns, M.C., Olejniczak, E.T., Waterson, A.G., Lee, T., Rossanese, O.W., Fesik, S.W., Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. Engl. 51 (2012), 6140–6143.
49. Sunaga, N., Shames, D.S., Girard, L., Peyton, M., Larsen, J.E., Imai, H., Soh, J., Sato, M., Yanagitani, N., Kaira, K., et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol. Cancer Ther. 10 (2011), 336–346.
50. Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J.J., Ladd-Acosta, C., Mesirov, J., Golub, T.R., Jacks, T., An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 37 (2005), 48–55.
51. Vallejo, A., Perurena, N., Guruceaga, E., Mazur, P.K., Martinez-Canarias, S., Zandueta, C., Valencia, K., Arricibita, A., Gwinn, D., Sayles, L.C., et al. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nat. Commun., 8, 2017, 14294.
52. Vartanian, S., Bentley, C., Brauer, M.J., Li, L., Shirasawa, S., Sasazuki, T., Kim, J.S., Haverty, P., Stawiski, E., Modrusan, Z., et al. Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines. J. Biol. Chem. 288 (2013), 2403–2413.
53. Weigelt, B., Lo, A.T., Park, C.C., Gray, J.W., Bissell, M.J., HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res. Treat. 122 (2010), 35–43.
54. Welsch, M.E., Kaplan, A., Chambers, J.M., Stokes, M.E., Bos, P.H., Zask, A., Zhang, Y., Sanchez-Martin, M., Badgley, M.A., Huang, C.S., et al. Multivalent small-molecule Pan-RAS inhibitors. Cell 168 (2017), 878–889.
55. Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A., et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67 (2011), 235–242.
56. Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H.G., Lim, S.M., Manandhar, A., Gondi, S., Sim, T., et al. Covalent guanosine mimetic inhibitors of G12C KRAS. ACS Med. Chem. Lett. 8 (2016), 61–66.